Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients

HJ Kim; TW Yoo; DI Park; JH Park; YK Cho; CI Sohn; WK Jeon; BI Kim; MK Kim; SW Chae; JH Sohn
May 2007
Annals of Oncology;May2007, Vol. 18 Issue 5, p892
Academic Journal
Background: In cholangiocarcinoma (CC), HER-2/neu protein overexpression has rarely been reported and the results are conflicting. The present study aimed to clarify the rates of HER-2/neu protein overexpression and gene amplification in human extrahepatic CC and to evaluate the correlation between HER-2/neu and several clinicopathologic features. Patients and methods: We investigated HER-2 gene amplification by chromogenic in situ hybridization (CISH) and HER-2/neu protein overexpression by immunohistochemistry in 55 extrahepatic CC patients who underwent curative surgery at our institution. Results: Overexpression of HER-2/neu protein (staining intensity score ≥ 2) was found in 16 out of 55 patients (29.1%). CISH revealed that HER-2 gene signals were increased in 10 out of 55 patients (18.1%). There was a positive and significant correlation between HER-2 gene amplification and HER-2/neu protein overexpression (Spearmans rho = 0.718, P < 0.01). In subgroup with lymph node metastases, HER-2 gene amplification by CISH was significant prognostic factor for survival (OR 43.6, 95% confidence interval 1.6–1219.6). Conclusions: HER-2/neu protein overexpression by HER-2 gene amplification may occur in human extrahepatic CC and constitute an independent prognostic factor in patients with lymph node metastases. In subgroup with lymph node metastases who exhibit HER-2/neu overexpression might constitute potential candidates for new adjuvant therapy, such as humanized monoclonal antibodies.


Related Articles

  • Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. Yan-Ming Zhou; Jia-Mei Yang; Bin Li; Zheng-Feng Yin; Feng Xu; Bin Wang; Peng Liu; Zhi-Min Li; Fava, Giammarco // World Journal of Gastroenterology;4/14/2008, Vol. 14 Issue 14, p2251 

    AIM: To explore clinicopathologic characteristics of intrahepatic cholangiocarcinoma (ICC) in patients with positive serum a-fetoprotein (AFP). METHODS: 131 patients who underwent surgical dissection for pathologically confirmed ICC were divided into a positive AFP (> 20 ng/mL) group (n = 32)...

  • HER2 Protein Overexpression in Infiltrating Ductal Carcinoma of the Breast Associated with Lymph Node Involvement. Lucarelli, Adrienne Pratti; Martins, Maria Marta; Oliveiraa, Vilmar Marques; Longo Galvão, Maria Antonieta; Guedes, João Marcelo; Rinaldi, José Francisco; Aoki, Tsutomo; Piato, Sebastião // American Journal of Applied Sciences;2009, Vol. 6 Issue 3, p445 

    The current study compares the rates of overexpression of the HER2 protein in stage II ductal carcinoma of breast in patients with lymph-node involvement. The research material was tissue sections obtained from the primary tumor of 28 patients with lymph-node involvement. The technique used to...

  • Histological step sectioning of pelvic lymph nodes increases the number of identified lymph node metastases. Engvad, Birte; Poulsen, Mads; Staun, Pia; Walter, Steen; Marcussen, Niels // Virchows Archiv;Jan2014, Vol. 464 Issue 1, p45 

    Pathological examinations of lymph nodes (LN) in prostate cancer patients are handled differently at various institutions. The objective of this study is to provide means to improve the guidelines by examining the impact of step sectioning on LN status in patients with intermediate and high-risk...

  • Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. Jung Wook Huh; Hyeong Rok Kim; Young Jin Kim; Huh, Jung Wook; Kim, Hyeong Rok; Kim, Young Jin // Journal of Gastrointestinal Surgery;Jul2010, Vol. 14 Issue 7, p1074 

    Background: The aim of the study was to evaluate factors for predicting lymph node metastasis in patients who had T1 and T2 colorectal cancer.Methods: A total of 224 patients with T1 or T2 colorectal cancers who underwent radical surgery with regional lymphadenectomy...

  • Breast Carcinoma With Micropapillary Features: Clinicopathologic Study and Long-Term Follow-Up of 100 Cases. Ling Chen; Yu Fan; Rong-gang Lang; Xiao-jing Gud; Yu-lan Sun; Li-fang Cui; Fang-fang Liu; Jia Wei; Xin-min Zhang; Li Fu // International Journal of Surgical Pathology;Apr2008, Vol. 16 Issue 2, p155 

    To study the clinicopathologic characteristics and prognosis of invasive micropapillary carcinoma of breast (IMPC), 100 cases of invasive breast carcinoma with an IMPC component were reviewed. Compared with invasive ductal carcinoma, not otherwise specified, with similar histologic grades,...

  • Pelvic lymph node dissection in the context of radical cystectomy: a thorough insight into the connection between patient, surgeon, pathologist and treating institution. Seiler, Roland; Thalmann, George N.; Zehnder, Pascal // Research & Reports in Urology;2013, Vol. 5, p121 

    Pelvic lymph node dissection (PLND) in patients with bladder cancer varies widely in extent, technique employed, and pathological workup of specimens. The present paper provides an overview of the existing evidence regarding the effectiveness of PLND and elucidates the interactions between...

  • Precision medicine and personalized breast cancer: combination pertuzumab therapy. Reynolds, Kerry; Sarangi, Sasmit; Bardia, Aditya; Dizon, Don S. // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p95 

    Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the...

  • Moving Forward: Herceptin[sup ®] in the Adjuvant Setting. Tan-Chiu, Elizabeth; Piccart, Martine // Oncology;2002 Supplement 1, Vol. 63, p57 

    HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy. Herceptin[sup ®] , an anti-HER2 monoclonal antibody, has shown significant efficacy in the treatment of HER2-positive metastatic...

  • Drug Delays CRPC Bone Metastases.  // Renal & Urology News;Jan2012, Vol. 11 Issue 1, p20 

    The article presents the findings of study of 1,432 men with castration-resistant prostate cancer (CRPC) conducted by researchers of Massachusetts General Hospital Medical Center in Boston which showed that the human monoclonal antibody denosumab can delay bone metastases in CRPC men.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics